Show simple item record

Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

dc.contributor.authorShakhnovich, Valentina
dc.contributor.authorMeibohm, Bernd
dc.contributor.authorRosenberg, Amy
dc.contributor.authorKierzek, Andrzej M.
dc.contributor.authorHasenkamp, Rachel
dc.contributor.authorFunk, Ryan S.
dc.contributor.authorThalhauser, Craig J.
dc.contributor.authorvan der Graaf, Piet H.
dc.contributor.authorWang, Yow-Ming C.
dc.contributor.authorHamuro, Lora
dc.date.accessioned2022-09-08T19:05:38Z
dc.date.available2022-09-08T19:05:38Z
dc.date.issued2019-11-25
dc.identifier.citationShakhnovich, V., Meibohm, B., Rosenberg, A., Kierzek, A.M., Hasenkamp, R., Funk, R.S., Thalhauser, C.J., van der Graaf, P.H., Wang, Y.-M.C. and Hamuro, L. (2020), Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. Clin Transl Sci, 13: 219-223. https://doi.org/10.1111/cts.12717en_US
dc.identifier.urihttp://hdl.handle.net/1808/33440
dc.description.abstractManaging immunogenicity in clinical practice and during drug development was a recent topic at the ASCPT 2019 annual meeting. This commentary expands on the discussion to facilitate a broader engagement across the community. The intent is to provide a rationale for ongoing research into the current gaps in assessing and interpreting immunogenicity in drug development and managing clinical immunogenicity for an approved drug. The following are highlighted: (i) Immunogenicity Considerations in Clinical Practice, (ii) Immunogenicity Testing and Current Limitations, (iii) Immunogenicity Risk Assessment and Mitigation, and (iv) Quantitative Systems Pharmacology (QSP) models of Immunogenicity.en_US
dc.publisherWiley Open Accessen_US
dc.rights© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_US
dc.titleImmunogenicity in Clinical Practice and Drug Development: When is it Significant?en_US
dc.typeArticleen_US
kusw.kuauthorFunk, Ryan S.
kusw.kudepartmentPharmacy Practiceen_US
dc.identifier.doi10.1111/cts.12717en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail
Name:
Shakhnovich_2020.pdf
Size:
572.8Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.
Except where otherwise noted, this item's license is described as: © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License.